![](https://venatorx.com/wp-content/uploads/2023/11/Venatorx_logo.png)
November 22, 2013
Venatorx Pharmaceuticals has completed a Series A financing round of approximately $3.5M from private investors to complement its other sources of funding and help advance its novel discovery and development programs.
![](https://venatorx.com/wp-content/uploads/2023/11/Venatorx_logo.png)
October 22, 2013
Venatorx Pharmaceuticals received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.
![](https://venatorx.com/wp-content/uploads/2023/11/Venatorx_logo.png)
September 16, 2013
Venatorx Pharmaceuticals was elected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M.
![](https://venatorx.com/wp-content/uploads/2023/11/Venatorx_logo.png)
September 1, 2013
Venatorx Pharmaceuticals was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. Venatorx may receive up to $3M of funding under the grant.
![](https://venatorx.com/wp-content/uploads/2023/11/Venatorx_logo.png)
August 1, 2013
Mr. Milano is the President, Chief Executive Officer, and Chairman of the Board of Directors of ViroPharma.
![](https://venatorx.com/wp-content/uploads/2023/11/Venatorx_logo.png)
May 20, 2013
Mr. Felker brings over 20 years of experience in biotechnology, pharmaceutical, and diagnostics, spanning business development, operations, and venture capital.